Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: 24-month results from the EVEREST II study

被引：0
|
作者：
Koh, Adrian H. C. [1 ]
Parikh, Soumil [2 ]
机构：
[1] Camden Med Ctr, Med Retina Eye & Retina Surg, Singapore, Singapore
[2] Novartis Pharma AG, Basel, Switzerland
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2018年 / 59卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
831
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Re: Oishi et al.: LAPTOP study: a 24-month trial of verteporfin versus ranibizumab for polypoidal choroidal vasculopathy (Ophthalmology 2014;121:1151-2) reply
    Oishi, Akio
    Oh, Hideyasu
    Mandai, Michiko
    Honda, Shigeru
    Miyamoto, Noriko
    OPHTHALMOLOGY, 2015, 122 (01) : E6 - E7
  • [32] Efficacy and Safety of Intravitreal Aflibercept in Polypoidal Choroidal Vasculopathy: 12-Month Results of the PLANET Study
    Lee, Won Ki
    Ogura, Yuichiro
    Iida, Tomohiro
    Chen, Shih-Jen
    Wong, Tien Yin
    Mitchell, Paul
    Ishibashi, Tatsuro
    Zhang, Eric
    Leal, Sergio
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [33] Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy - One-year results of a prospective case series
    Chan, WM
    Lam, DSC
    Lai, TYY
    Liu, DTL
    Li, KKW
    Yao, Y
    Wong, TH
    OPHTHALMOLOGY, 2004, 111 (08) : 1576 - 1584
  • [34] Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy: Two-Year Results of the Aflibercept in Polypoidal Choroidal Vasculopathy Study
    Wong, Tien Yin
    Ogura, Yuichiro
    Lee, Won Ki
    Iida, Tmohiro
    Chen, Shih-Jen
    Mitchell, Paul
    Cheung, Chui Ming Gemmy
    Zhang, Zhongqi
    Leal, Sergio
    Ishibashi, Tatsuro
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2019, 204 : 80 - 89
  • [35] 1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy
    Ian Y. Wong
    Xuan Shi
    Rita Gangwani
    Paul Zhao
    Lawrence P. Iu
    Qing Li
    Alex Ng
    Xiaoxin Li
    BMC Ophthalmology, 15
  • [36] INITIAL VERSUS DELAYED PHOTODYNAMIC THERAPY IN COMBINATION WITH RANIBIZUMAB FOR TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY The Fujisan Study
    Gomi, Fumi
    Oshima, Yuji
    Mori, Ryusaburo
    Kano, Mariko
    Saito, Masaaki
    Yamashita, Ayana
    Iwata, Eiji
    Maruko, Ruka
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2015, 35 (08): : 1569 - 1576
  • [37] 1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy
    Wong, Ian Y.
    Shi, Xuan
    Gangwani, Rita
    Zhao, Paul
    Iu, Lawrence P.
    Li, Qing
    Ng, Alex
    Li, Xiaoxin
    BMC OPHTHALMOLOGY, 2015, 15
  • [38] Ranibizumab versus verteporfin photodynamic therapy for myopic choroidal neovascularization: Results from RADIANCE
    Steinle, Nathan
    Ghanekar, Avanti
    Quezada-Ruiz, Carlos
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [39] Comparison of one-year results of photodynamic therapy combined with ranibizumab or aflibercept for treating polypoidal choroidal vasculopathy
    Ito, Arisa
    Maruyama-Inoue, Maiko
    Kitajima, Yoko
    Sato, Shimpei
    Inoue, Tatsuya
    Yamane, Shin
    Kadonosono, Kazuaki
    PLOS ONE, 2020, 15 (06):
  • [40] Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy
    Jain, Prashant
    Anantharaman, Giridhar
    Gopalakrishnan, Mahesh
    Goyal, Anubhav
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2018, 66 (08) : 1119 - 1127
12345